Myopic Macular Degeneration: Understanding Pathologic Myopia and Protecting Your Vision

Myopic macular degeneration (MMD), also known as pathologic or degenerative myopia, is a sight-threatening complication of high axial myopia—typically defined as a refractive error of ≤−6.00 diopters or an axial length of ≥26.5 mm. When the eyeball elongates excessively, it stretches and thins the posterior sclera, choroid, and retina, producing structural changes at the macula that can lead to irreversible central vision loss. MMD is a leading cause of visual impairment in East Asia and its prevalence is rising worldwide alongside the global myopia epidemic.

Key Pathologic Features: The META-PM Classification

Clinicians use the META-PM (Meta-Analysis for Pathologic Myopia) classification to grade the severity of macular changes:

  • Category 0: No lesions present.
  • Category 1: Tessellated fundus only—choroidal vessels become visible through a thinned retinal pigment epithelium.
  • Category 2: Diffuse chorioretinal atrophy.
  • Category 3: Patchy chorioretinal atrophy.
  • Category 4: Macular atrophy (resembling geographic atrophy) ± lacquer cracks.
  • Plus lesions: Lacquer cracks (breaks in Bruch's membrane), Fuchs spot (subretinal hemorrhage/scarring), choroidal neovascularization (CNV), dome-shaped macula, and posterior staphyloma.

Risk Factors

  • High myopia: ≤−6.00 D; risk increases exponentially with each additional diopter.
  • Age: Cumulative damage; prevalence rises significantly after age 50.
  • Genetics: Family history of high myopia or MMD.
  • Environmental: Excessive near work and limited outdoor time drive myopia onset and progression.
  • Systemic: Smoking, hypertension, and diabetes accelerate choroidal vascular compromise.

Symptoms

  • Gradual central vision blurring or distortion (metamorphopsia).
  • Difficulty reading, driving, or recognizing faces.
  • Central scotoma (blind spot).
  • Faded color vision.
  • Sudden vision drop suggests choroidal neovascularization (CNV)—urgent evaluation is critical.

Diagnosis

  • Dilated fundus examination with widefield imaging.
  • OCT (Optical Coherence Tomography): Assesses retinal and choroidal thickness, detects CNV, maps atrophy.
  • OCT-A (OCT Angiography): Non-invasive evaluation of CNV and choriocapillaris flow.
  • Fundus Autofluorescence (FAF): Tracks atrophy progression.
  • Axial length measurement (IOLMaster/Lenstar): Establishes baseline for monitoring progression.

Management

  • Active CNV: Anti-VEGF intravitreal injections (aflibercept, ranibizumab, bevacizumab) are first-line. Photodynamic therapy is rarely used. Early treatment preserves vision.
  • Atrophic MMD (no CNV): No proven therapy reverses atrophy. Complement inhibitors (pegcetacoplan, avacincaptad pegol) approved for geographic atrophy in AMD are being studied off-label for MMD.
  • Low vision rehabilitation: Essential at all stages—magnifiers, CCTV, eccentric viewing training.
  • Myopia control (prevention): In children: orthokeratology, low-dose atropine, multifocal contact lenses, increased outdoor time—reduces future MMD risk.

Monitoring

  • High myopes: Annual dilated exam + OCT/OCT-A.
  • Known MMD: Every 6–12 months; sooner if symptoms change.
  • Self-monitor with Amsler grid weekly.

MMD is a lifelong condition requiring specialist care. Early detection, prompt CNV treatment, and low vision support maximize visual potential and quality of life.

Eye & Vision Disorders - Related Articles